Download File - JOHN J. HADDAD, Ph.D.
Download File - JOHN J. HADDAD, Ph.D.
Download File - JOHN J. HADDAD, Ph.D.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Index 209<br />
DC. See Dendritic cells (DC)<br />
DC-based immunotherapy, for gliomas<br />
acid-eluted autologous tumor peptides<br />
in, 92–93<br />
CTL assays in, 93<br />
DC-glioma fusion cell vaccine, 91<br />
future strategies for, 98–99<br />
CD8 þ RTEs in, 104<br />
CSC in, 99<br />
summary of clinical trials, 100–103<br />
TIL and, 93–94<br />
tumor lysate-pulsed DC, 89–91<br />
intradermal vaccination of, 91–92<br />
DC-glioma fusion cell vaccine, 91<br />
Delayed type hypersensitivity (DTH),<br />
58, 59<br />
Dendritic cells (DC), 86, 119, 121, 135<br />
autologous, 71, 74<br />
cathepsin S in, 8<br />
in CD8 þ -cell priming, 19–20<br />
GILT expression in, 9<br />
immunotherapy for gliomas<br />
(See DC-based immunotherapy,<br />
for gliomas)<br />
long peptides processing by, 15–16<br />
proteasomes of, 19<br />
proteins at surface of, 11<br />
states of, 19<br />
subset, 19<br />
therapy, 71<br />
vaccines for gliomas (See DC-based<br />
immunotherapy, for gliomas)<br />
Dermis. See Dendritic cells (DCs)<br />
Devitalization process, 73<br />
DFS. See Disease-free survival (DFS),<br />
in cancer patients<br />
Disease-free survival (DFS), in cancer<br />
patients, 58<br />
D122 lung cancer cells, 37<br />
DNA immunization, 132–135<br />
DNA sequences, 134, 137<br />
DNA vaccines<br />
advantages of, 135–137<br />
immunization of, 132–135<br />
prime-boost strategies for,<br />
137–141<br />
strategies to improve, 141–145<br />
Docetaxel, 41<br />
Drugs development. See also<br />
Investigational drugs<br />
conventional approach in, 177–178<br />
epitope targeted approach in, 168<br />
innovative technologies in, 175<br />
investigational data analysis in,<br />
176–177<br />
linear process of, 153<br />
molecular targeted therapies for, 152<br />
optimized approach of, 177<br />
preclinical and clinical models for,<br />
154–164<br />
second- and third-generation of, 176<br />
translational approach in, 169–175<br />
DTH. See Delayed type hypersensitivity<br />
(DTH)<br />
E75. See HER2/neu peptide<br />
vaccine (E75)<br />
EGFP-Ub, detection of, 15<br />
Electroporation, 139–140<br />
ELISA assay, 118, 120. See also<br />
ELISPOT assay<br />
ELISPOT assay, 194<br />
monitoring of MKC1106-PP, 195<br />
Endo/lysosomal enzymes, 7–8<br />
Endosomal maturation, stages of, 8<br />
Endpoints, clinical, 152<br />
Epitope targeted approach,<br />
hypothetical, 168<br />
ERAAP in mice, 6–7<br />
Favld, 75<br />
FDA. See Food and Drug Administration<br />
(FDA)<br />
FFPE. See Formalin-fixed<br />
paraffin-embedded (FFPE)<br />
flt3 ligand, 121<br />
Fluorophores, organic and inorganic, 188<br />
Follicular B-cell non-Hodgkin’s<br />
lymphoma, 75<br />
Food and Drug Administration (FDA),<br />
United States, 196–197<br />
Formalin-fixed paraffin-embedded<br />
(FFPE), tumor samples<br />
detection of mRNA, 184